Trial Profile
Phase II Study of Bevacizumab-containing Regimen in Patients With Metastatic Colorectal Cancer Who Failed to Cytotoxic Treatment
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms BATTLE
- 31 Aug 2020 Planned number of patients changed from 30 to 46.
- 21 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 21 Aug 2020 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.